-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
(Medical Health News July 26, 2021)
Cinda Biopharmaceuticals, a biopharmaceutical company dedicated to the development, production and sales of innovative drugs for the treatment of tumors, metabolic diseases, autoimmunity and other major diseases announced its anti-PD-1/TIGIT bispecific antibody (R&D code: IBI321 ) Phase 1 clinical study completed the first patient administration in China
.
This study is an open, phase 1a dose escalation and expansion study to evaluate the safety, tolerability and preliminary efficacy of IBI321 in patients with advanced malignant tumors in China.
The main purpose of the study is to evaluate the dual specificity of IBI321.
The safety, tolerability and anti-tumor activity of sex antibodies in subjects with advanced malignant solid tumors who have failed standard therapies
.
IBI321 is an anti-PD-1 and anti-TIGIT dual antibody that specifically targets PD-1 and TIGIT.
It has a synergistic effect on the mechanism of action and has more advantages, thereby improving efficacy and safety
.
The results of various preclinical studies have shown that IBI321 retains the pharmacodynamic activity of PD-1 inhibitors, and at the same time inhibits the signal of TIGIT, and synergistically enhances the efficacy
Professor Han Baohui, director of the Respiratory Department of Shanghai Chest Hospital and director of GCP, pointed out: “Although immune checkpoint inhibitors have shown surprising effects in the treatment of various tumors, they still face many new challenges, such as immunity.
Primary, secondary drug resistance, etc.
At the same time, the efficacy of immune checkpoint inhibitors needs to be further improved
.
Therefore, the development of the next generation of bispecific immune checkpoint inhibitors has important clinical significance and value.
Professor Cheng Xiangdong, Secretary of the Party Committee of the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and director of the Zhejiang Upper Gastrointestinal Tumor Research Center Anti-progress in melanoma, lung cancer, and esophageal cancer.
The progress of immunotherapy in colorectal cancer and some gastric cancers is not satisfactory.
Dr.
Zhou Hui, Senior Vice President of Clinical Development of Cinda Biopharmaceutical Group, said: “The design principle of the PD-1/TIGIT dual antibody is that it can specifically target PD-1 and TIGIT at the same time, and specifically target the PD-1 axis at the same time.
The TIGIT/CD155 signal pathway enhances the tumor-killing activity of T cells and NK cells.
It can also bridge PD-1 and TIGIT on the same cell to further relieve immunosuppression, thereby improving the efficacy and safety of single-drug use
.
At present, there is no equivalent in the world.
